Apps may be available on your phone to help you monitor your wet AMD symptoms and assist you with everyday tasks such as reading, texting, and identifying objects. Advanced neovascular age-related ...

AMD primarily affects central vision, complicating activities like reading and driving, but does not cause complete blindness. Wet AMD involves abnormal blood vessel growth, while dry AMD progresses ...

Brolucizumab stabilizes retinal exudation and fluid, improving visual outcomes in wet AMD management. Study showed BCVA and CRT improvements at 6 and 12 months, with minimal adverse events. Small ...

Age-related macular (AMD) degeneration is a leading cause of vision impairment and blindness in the elderly population. In so-called wet AMD, new, abnormal blood vessels grow in the central part of ...

Age-related macular (AMD) degeneration is a leading cause of vision impairment and blindness in the elderly population. In so-called wet AMD, new, abnormal blood vessels grow in the central part of ...

Please provide your email address to receive an email when new articles are posted on . Sura-vec injection reduced the annualized anti-VEGF injection rate by 76% with a high dose and 77% with a low ...

Carl Zeiss Meditec AG and Oraya Therapeutics, Inc. (Oraya) jointly announced today that the companies have entered into a collaboration agreement under which Carl Zeiss Meditec will provide funding to ...

Shares of Ocular Therapeutix (NASDAQ:OCUL) spiked on Wednesday after the company said its Phase 3 registrational trial SOL-R for its lead asset Axpaxli for the eye disorder wet age-related macular ...

Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular ...

Axpaxli is Ocular's main value driver, targeting a large wet AMD market with a differentiated, sustained-release TKI mechanism. DEXTENZA sales are declining, making Ocular increasingly dependent on ...